CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotech

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) wi

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation,

Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances m

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.18 per share versus the Zacks Con

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the anal

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the Europea

Beam Therapeutics offers compelling upside, with a $2.64B market cap and a promising gene-editing pi

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotech

Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) has received an average recommendation of "M

Amova Asset Management Americas Inc. lowered its stake in Beam Therapeutics Inc. (NASDAQ: BEAM) by 1

Beam Therapeutics' growing pipeline could reward patient investors.

Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing cont

Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dis

Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its A

B of A Securities analyst Alec Stranahan reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy an

Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destr

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) wi

Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpar

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names whe

Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-target

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines

BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Maj

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc

BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runw

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine

Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Tran

BEAM-302 is being evaluated in a Phase 1/2, open-label, dose exploration and dose expansion clinical

Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform a

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.91) per share which beat the analys

Jim Cramer discussed various stocks on Mad Money Lightning Round. He expressed concerns about Ondas

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq

Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Tre

Citigroup analyst Samantha Semenkow maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and rais

Beam Therapeutics shares rise after BEAM-302 trial data show sustained AAT levels above threshold, s

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patient

Termination of License Agreement with Bio Palette Co., Ltd. – Activation of Standby License from Kob

RBC Capital analyst Luca Issi maintains Beam Therapeutics (NASDAQ:BEAM) with a Sector Perform and

Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform an

Beam Therapeutics (NASDAQ: BEAM) shares are rising Tuesday after the company reported quarterly resu

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.10) per share which beat the analys

Canaccord Genuity analyst Whitney Ijem initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with

Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform a